Download PDF Algorithm for the management of moderate to severe psoriasis1 Click to enlarge BSA: body surface area; PASI: psoriasis area and severity index; ∆PASI: change of PASI from baseline until the time of evaluation; DLQI: dermatology life quality index. The DLQI is a widely used scale which is available online free of charge for […]
MIMS Ireland two new symbols
January 10, 2014 by Leave a Comment
Following a number of new regulations introduced in Ireland last year, MIMS Ireland is pleased to announce the addition of two new symbols designed to further guide healthcare professionals in their drug choice or drug safety monitoring. 1) First symbol – under additional monitoring: Identifies medicinal products which require additional monitoring as recently defined […]
Stelara Receives Approval for Active Psoriatic Arthritis
January 10, 2014 by Leave a Comment
Download Pdf Janssen wish to announce that the European Commission has approved the use of Stelara (ustekinumab), alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.1 Stelara, a human anti-interleukin (IL)-12 and IL-23 monoclonal […]
Anti-doping: 2014 Guide for Prescribers
January 1, 2014 by Leave a Comment
The World Anti-Doping Code, published by the World Anti-Doping Agency (WADA), harmonises anti-doping regulations across all sports and in all countries. This Code includes a list of substances and methods which are prohibited in sport. Some of these substances are contained in medicinal products marketed in Ireland. However, in recognition of the fact that some […]
Changes to the WADA Prohibited List 2014
January 1, 2014 by Leave a Comment
The World Anti-Doping Agency (WADA) has published the 2014 List of substances and methods prohibited for use in sport. See MIMS Ireland Summary of the WADA 2014 List. Changes to the Prohibited List are as a result of ongoing reviews by the WADA List Expert Group who review the list annually, taking into consideration submissions […]
Capecitabine Sandoz
January 1, 2014 by Leave a Comment
Company: Rowex Ltd. Legal category: Prescription. High Tech. Sport permitted. Active ingredient: Capecitabine 150mg, 500mg. Description: Light pink or pink film-coated tablet of modified oval shape marked 150 or 500 on one side, respectively. Presentation: 150mg-60, €27.27; 500mg-120, €180.93. Indications: Adjuvant treatment following surgery of stage III (Dukes’ stage C) colon cancer. Treatment of metastatic […]
Jaydess
January 1, 2014 by Leave a Comment
Company: Bayer Ltd. Legal category: Prescription. GMS. Sport permitted. Active ingredient: Levonorgestrel 13.5mg. Description: Intrauterine delivery system. Presentation: 1, €97.10. Indications: Contraception. Pharmacology: The high levonorgestrel concentration in the endometrium down-regulates endometrial estrogen and progesterone receptors. The endometrium becomes relatively insensitive to the circulating estradiol and a strong antiproliferative effect is seen. Morphological changes of […]
Telmisartan Clonmel
January 1, 2014 by Leave a Comment
Company: Clonmel Healthcare Ltd. Legal category: Prescription. GMS. Sport permitted. Active ingredient: Telmisartan 20mg, 40mg, 80mg. Description: Yellow film-coated tablets with 20, 40 or 80 marked on one side and T on reverse, respectively. 20mg: Circular shaped. 40mg, 80mg: Capsule shaped. Presentation: 20mg-28, €6.42; 40mg-28,€7.61; 80mg-28, €9.95. Indications: Treatment of essential hypertension. Reduction of cardiovascular […]
Telmisartan Rowex
January 1, 2014 by Leave a Comment
Company: Rowex Ltd. Legal category: Prescription. GMS. Sport permitted. Active ingredient: Telmisartan 20mg, 40mg, 80mg. Description: White plain tablets marked 20, 40 or 80 on one side, respectively. Can be divided into equal halves. 20mg: Round. 40mg, 80mg: Oblong, scored on one side. Presentation: 20mg-28, €6.42; 40mg-28,€7.61; 80mg-28, €9.95. Indications: Treatment of essential hypertension. Reduction […]
Loading ...
